

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

## **COMP/M.5614 – SANOFI-AVENTIS / MERIAL**

### **SECTION 1.2**

#### **Description of the concentration**

On 11 August 2009, the Commission received a notification pursuant to Article 4 of Council Regulation (EC) No 139/2007 of a proposed concentration by which Sanofi-Aventis' control over Merial will change from joint control to sole control within the meaning of Article 3(1)(b) of the Council Regulation.

The business activities of the undertakings are:

- For Sanofi-Aventis: research, development, manufacture and marketing of human healthcare products, including vaccines, both throughout the EU and worldwide.
- For Merial: research, development, manufacture and marketing of animal health products, including vaccines both throughout the EU and worldwide.

As the Transaction will consist of the transition from joint control to sole control, and since there are no horizontal overlap and negligible vertical overlaps, Sanofi-Aventis considers that the Transaction should properly be notified via Short Form CO.